FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN) in a report released on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently weighed in on the stock. William Blair reiterated a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th. HC Wainwright upgraded shares of FibroGen to a “strong-buy” rating in a report on Tuesday, December 17th.

FibroGen Stock Up 14.2 %

FGEN opened at $0.52 on Thursday. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.80. The company has a market cap of $52.48 million, a P/E ratio of -0.42 and a beta of 0.75. The firm’s 50-day moving average price is $0.49 and its 200-day moving average price is $0.43.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.21. The company had revenue of $46.33 million for the quarter, compared to analyst estimates of $34.00 million. During the same quarter last year, the company earned ($0.52) EPS. On average, research analysts anticipate that FibroGen will post -0.8 EPS for the current fiscal year.

Hedge Funds Weigh In On FibroGen

Several hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd boosted its position in FibroGen by 423.8% in the 4th quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 77,693 shares in the last quarter. Franklin Street Advisors Inc. NC boosted its position in FibroGen by 100.0% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 100,000 shares in the last quarter. FMR LLC boosted its position in FibroGen by 21.8% in the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 68,569 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in FibroGen in the 3rd quarter worth approximately $307,000. Finally, Geode Capital Management LLC boosted its position in FibroGen by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after purchasing an additional 32,884 shares in the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.